FDA Authorizes Marketing of Diagnostic Aid for Autism Spectrum Disorder

FDAThe U.S. Food and Drug Administration authorized marketing of a device to help diagnose autism spectrum disorder (ASD). The Cognoa ASD Diagnosis Aid is a machine learning-based software intended to help health care providers diagnose ASD in children 18 months through 5 years of age who exhibit potential symptoms of the disorder.

"Autism spectrum disorder can delay a child’s physical, cognitive and social development, including motor skill development, learning, communication and interacting with others. The earlier ASD can be diagnosed, the more quickly intervention strategies and appropriate therapies can begin," said Jeff Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. "Today's marketing authorization provides a new tool for helping diagnose children with ASD."

The Centers for Disease Control and Prevention defines ASD as a "developmental disability that can cause significant social, communication and behavioral challenges" and is estimated to affect about 1 in 54 children. Because ASD symptoms can vary greatly, the disorder may be difficult to diagnose. While ASD may be detected as early as 18 months old, many children are not diagnosed until later in childhood, which can delay treatment and early intervention. The average age of diagnosis for ASD is 4.3 years. Some delays in diagnosis are due to the need for children to be referred to specialists with expertise in ASD.

The Cognoa ASD Diagnosis Aid is a software as a medical device that uses a machine learning algorithm to receive input from parents or caregivers, video analysts and health care providers to assist physicians evaluate a patient at risk of ASD. The device consists of three main components: a mobile app for caregivers and parents to answer questions about behavior problems and to upload videos of their child; a video analysis portal that allows manufacturer-trained and certified specialists to view and analyze uploaded videos of patients; and a health care provider portal that is intended for a health care provider to enter answers to pre-loaded questions about behavior problems, track the information provided by parents or caregivers and review a report of the results. After processing the information provided by parents, caregivers and healthcare providers, the ASD Diagnosis Aid reports a positive or negative diagnosis if there is sufficient information for its algorithm to make a diagnosis. If there is insufficient information to render a "Positive for ASD" or "Negative for ASD" result to help determine a diagnosis, the ASD Diagnosis Aid will report that no result can be generated.

The FDA assessed the safety and effectiveness of the Cognoa ASD Diagnosis Aid in a study of 425 patients aged 18 months through 5 years in 14 different clinical care sites, with an average age of 2.8 years. The study compared the assessments made by the device directly against the assessments made by a panel of clinical experts who used the current standard ASD diagnostic process. The device provided a "Positive for ASD" or "Negative for ASD" result to aid in making a diagnosis in 32% of patients. For those with a "Positive for ASD" or "Negative for ASD" result, the device results matched the panel's conclusions for 81% of patients who tested positive for ASD by the device and 98% of patients who tested negative for ASD by the device. In addition, the device made an accurate ASD determination in 98.4% of patients with the condition and in 78.9% of patients without the condition.

The risks associated with the use of the device include misdiagnosis and delayed diagnosis of ASD, based on a false positive result (observed in 15 out of 303 study subjects without ASD), a false negative result (observed in one out of 122 study subjects with ASD) or when no result was generated. Both misdiagnosis or missed diagnosis can result in delayed treatment of ASD and delivery of treatment not appropriate for ASD.

The FDA reviewed the Cognoa ASD Diagnosis Aid through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this authorization, the FDA is establishing special controls for devices of this type, including requirements related to labeling and performance testing. When met, the special controls, along with general controls, provide reasonable assurance of safety and effectiveness for devices of this type. This action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA's 510(k) premarket process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

The Cognoa ASD Diagnosis Aid is indicated as an aid in the diagnosis of ASD for patients 18 months through 5 years of age who are at risk of developmental delay based on concerns of a parent, caregiver, or health care provider. The device is not indicated for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process.

The FDA granted the marketing authorization to Cognoa, Inc.

About the U.S. Food and Drug Administration (FDA)

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Most Popular Now

Open Call HORIZON-HLTH-2021-TOOL-06-03: …

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 "Unlocking the full potential of new tools, technologies and digital...

CSAM Acquires Optima - Further Boosts eH…

CSAM Health Group AS ("CSAM"), the leading provider of niche eHealth solutions in the Nordics, today announced it has signed a deal to acquire eHealth player Optima Corporation Ltd from...

Novartis and Hewlett Packard Enterprise …

Novartis and Hewlett Packard Enterprise (HPE)announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to...

COVID-19 Origins Still a Mystery

Scientists using computer modelling to study SARS-CoV-2, the virus that caused the COVID-19 pandemic, have discovered the virus is most ideally adapted to infect human cells - rather than bat...

Using Artificial Intelligence to Overcom…

Depression is a worldwide problem, with serious consequences for individual health and the economy, and rapid and effective screening tools are thus urgently needed to counteract its increasing prevalence. Now...

Deep Machine Learning Completes Informat…

The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has...

EU Digital COVID Certificate Enters into…

The EU Digital COVID Certificate Regulation enters into application. This means that EU citizens and residents will now be able to have their Digital COVID Certificates issued and verified across...

Philips and the Spanish National Center …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has participated in an important research project to develop a magnetic resonance (MR) imaging technique [1,2] that could...

Scottish Health and Care Professionals G…

Scottish health and care professionals across a wide range of clinical settings including NHS Scotland health boards are being given access to an individual's COVID-19 vaccine status through the Orion...

Ethics and Governance of Artificial Inte…

Artificial Intelligence (AI) refers to the ability of algorithms encoded in technology to learn from data so that they can perform automated tasks without every step in the process having...

It's Going to be Quite a Handover…

Health and social care secretary Matt Hancock has been abruptly replaced by Sajid Javid. The Highland Marketing advisory board consider the huge agenda he is now facing, and what it...

Philips Accelerates Stroke Diagnosis and…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced a strategic partnership agreement with NICO.LAB, a MedTech stroke care company. Together with the recently expanded stroke...